Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

employee- and office-related expenses.

-- In the fourth quarter ended December 31, 2007, Sunesis recorded a $0.3

million additional restructuring charge as a result of the company's

reorganization and reduction in force in the third quarter of 2007.

For the year ended December 31, 2007, an aggregate of $1.6 million in

restructuring charges was recorded. Cash restructuring costs accounted

for approximately $1.1 million of the total $1.6 million restructuring

charge for the year.

-- Sunesis reported a net loss of $8.8 million for the fourth quarter of

2007 and of $38.8 million for the twelve-month period ended December

31, 2007, compared to a reported net loss of $9.0 million and $31.2

million, respectively, for the three-month and twelve-month periods

ended December 31, 2006.

-- In 2008, Sunesis expects net cash used in operating activities of

approximately $30 million - $35 million in the absence of any new

collaborations, compared to $34.5 million in 2007. A decrease in net

cash used in operating activities is anticipated primarily due to the

reorganization effected in August of last year, partially offset by

increased costs associated with clinical trial and other development

activities for SNS-595, SNS-032 and SNS-314.

Conference Call Information

Sunesis' management will host a conference call to review the results of the fourth quarter and the 2007 fiscal year today at 10:30 a.m. EDT. Individual and institutional investors can access the call via 877-604-9668 (U.S. and Canada) or 719-325-4904 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website severa
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... , July 30, 2015  With over 60,000 customers across the globe, ISN improves ... 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over ... Headquartered in Dallas, TX ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... June 26 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... yesterday on its monoclonal antibody product, Angiolix(R), at,the ... Dublin,Ireland. Dr. Agamemnon Epenetos, Access, Chief Scientific Officer ... potential to prevent,the growth of cancer stem cells., ...
... Ill. Now you see it, soon you might ... In computer simulations, the researchers have demonstrated an approximate ... crystals. The mathematical proof brings scientists a step closer ... is much more than a theoretical exercise," said Harley ...
... felt a down economy at all. PHC Consulting is focused on ... clinical and research, physician call points, medical devices, pharmaceutical, etc). So ... that growth to a strong web presence. , ... ...
Cached Biology Technology:Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells 2Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells 3Silicon photonic crystals key to optical cloaking, researchers say 2Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Restoring the Everglades: The Fourth Biennial Review, 2012 -- ... Council -- assesses progress in the Comprehensive Everglades Restoration ... that aims to reverse the ecosystem,s decline while meeting ... is the fourth biennial evaluation of CERP, which was ...
... New Zealand, June 19, 2012 Digicel Pacific Limited, a ... Digicel Group, today announced it is deploying biometric enabled payment ... Mobile Money customers a more convenient way to send money ... enables customers sending money home to register just once and ...
... Neuchtel, Switzerland, June 19, 2012 - Reaxys announces the ... original research in organic, organometallic and inorganic chemistry, the ... by leading young chemists across the globe. ... Gregory Hamilton at University of California, Berkeley USA Debashis ...
Cached Biology News:Digicel Launches World's First Biometric Identification System For International Money Transfers 2Digicel Launches World's First Biometric Identification System For International Money Transfers 3Reaxys announces winners of the 2012 Reaxys Ph.D. Prize 2
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
... combine high durability and capacity with ... use. The patented triple-counterbalanced heavy-duty mechanism ... run at high speed with heavy, ... range is delivered with tight uniformity ...
Small bottle for hybridization 150 x 35mm...
Medium bottle for hybridization 250 x 35mm...
Biology Products: